Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 12/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14931007 | 0.80 | CDA (0.67) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL587511 | 0.79 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL13030857 | 0.79 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL586883 | 0.79 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL18575668 | 0.79 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL13030832 | 0.74 | CDA (0.63) | CDASLC29A1 | |
| SCHEMBL12338468 | 0.73 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL19656107 | 0.73 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL20788714 | 0.73 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL25713917 | 0.73 | CDA (1.00) | CDAPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040501-B2 | Compositions and methods for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130116207-A1 | Compositions and Methods for Treating Cancer | EISAI INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8329666-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329665-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8324180-B2 | Compositions and methods for treating cancer | EISAI INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279967-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221305-A1 | Compositions and Methods for Treating Cancer | RNASE1, UNG, HCCS | CDA 537/4885PDE4D 2388/4885PDE3A 1457/4885 |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | CDA 537/4885PDE4D 2388/4885PDE3A 1457/4885 |
| US-20100279967-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNG, DUT, DCTD | CDA 49/4885PDE4D 1128/4885PDE3A 656/4885 |
| US-20130116207-A1 | Compositions and Methods for Treating Cancer | RNASE1, UNG, HCCS | CDA 537/4885PDE4D 2388/4885PDE3A 1457/4885 |
| US-20100279966-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | CDA 537/4885PDE4D 2388/4885PDE3A 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.